
Apyx Medical fell 32.9% from $3.81 to $2.56, behind the S&P 500's +11.0%. Its worst day was Sep 28 (−15.5%), and its low came Oct 8 at $2.36.
Nov 18, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Apyx Medical shares rose 14.9%, while the S&P 500 rose 0.2%.
+14.9% · S&P 500 +0.2%
EPS of $-0.03 beat the $-0.06 estimate on $19.2M revenue (est. $19.1M); FY revenue guidance of $57.5M–$58.5M against the $55.9M consensus.
Story events cover the past 12 months · Times ET
+0.6% · S&P 500 −0.2%
Apyx Medical shares rose 14.4%, while the S&P 500 rose 1.1%.
+14.4% · S&P 500 +1.1%
EPS of $-0.05 beat the $-0.11 estimate on $12.5M revenue (est. $11.0M); FY revenue guidance of $59.0M–$60.0M against the $57.9M consensus.
+21.9%, the year's best day · S&P 500 −0.3%
In this study, 22 patients received a single treatment session combining these modalities to address both the structural and surface level causes of cellulite and skin laxity.
+12.1% · S&P 500 +0.2%
Apyx Medical closed at its highest level of the year, 27.6% above where the year started.
+1.9% · S&P 500 −0.3%
EPS of $-0.07 beat the $-0.09 estimate on $13.9M revenue (est. $13.3M); FY revenue guidance of $59.0M–$60.0M against the $59.6M consensus.
−2.6% · S&P 500 +0.6%
Apyx Medical shares fell 15.5%, while the S&P 500 fell 0.7%.
−15.5%, the year's worst day · S&P 500 −0.7%
Apyx Medical closed at its lowest level of the year, 38.1% below where the year started.
−7.5% · S&P 500 −0.4%
EPS of $-0.04 beat the $-0.09 estimate on $14.0M revenue (est. $13.4M); FY revenue guidance of $59.0M–$60.0M against the $59.4M consensus.
+18.1%, on 995K shares, the year's heaviest volume · S&P 500 −4.4%
Where it ended: a close of $2.56 on Nov 17, 2026. Up next: Q4 2026 earnings on Mar 9, 2027 (EPS est. $-0.04, revenue est. $19.2M).
Nothing in the past 12 months.
All APYX dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for APYX and SPY from Benzinga historical bars. Not investment advice.